Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.
Did you mean: order of-- -?

Amazon Pharmacy Expands Same-Day Delivery and Kiosk Access for New Ozempic® Pill

Amazon Pharmacy a full-service digital pharmacy that delivers medications directly to customers' homes, is expanding access to Novo Nordisk's Ozempic® pill, the only FDA-approved oral GLP-1 medication to treat type 2 diabetes. Amazon Pharmacy will...

Novo Nordisk’s Ozempic pill—the only FDA-approved oral peptide GLP-1 for adults with Type 2 Diabetes—will soon be available in the U.S

Novo Nordisk announced that starting Monday, May 4, Ozempic® (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes in the US. Ozempic® is the only FDA-approved oral peptide GLP-1 medication for adults with...

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

TIME has named Sprout Pharmaceuticals among just 10 organizations globally shaping the future of health and life sciences. This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi. In December 2025, the...

Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

YARAL Pharma Inc. the rapidly growing U.S. generics subsidiary of IBSA (Institut Biochimique SA), announced that its Diclofenac Epolamine Topical System 1.3%, the authorized generic of Flector® (diclofenac epolamine) topical system 1.3%, is now...

Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

SQ Innovation, developer of Lasix® ONYU, announced two important regulatory milestones in its international expansion strategy: the receipt of a CE marking certificate for the Lasix ONYU device, and the acceptance of Lasix ONYU by the European...

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2...

OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

OrthoTrophix, Inc., a privately held biopharmaceutical company, today announced new clinical data demonstrating a significant association between femoral subchondral bone shape, measured by B-score, and meniscal pathology in patients with knee...

CRENESSITY® lowers glucocorticoid doses while maintaining androgen control in adults with classic congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial reductions in glucocorticoid (GC) doses in adults with classic congenital adrenal...

Avantor® Expands Stability and Microbial Testing Facility to Enhance U.S. Biomanufacturing Infrastructure

Avantor, Inc. a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the expansion of its North American quality control capabilities with the addition of...

Peer-reviewed validation of a 60-channel closed-loop neurostimulation brain implant is published by Nia Therapeutics

Nia Therapeutics announced publication in Brain Stimulation of the first in vivo validation of its Smart Neurostimulation System (SNS), a wireless, implantable brain-computer interface designed for closed-loop treatment of memory disorders. The...

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

Jazz Pharmaceuticals plc announced that the company will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting taking place November 19-23 in Honolulu, Hawaii. The presentations will feature both clinical and...

LOTUS study data on DAYBUE® (trofinetide) for Rett Syndrome's long-term efficacy and tolerability is published in Developmental Medicine and Child Neurology

Acadia Pharmaceuticals Inc. announced that the journal Developmental Medicine and Child Neurology published interim results from the caregiver-reported observational online, open-label, ongoing LOTUS study evaluating effectiveness and tolerability...

Optune Lua® from Novocure has received approval in Japan for treating unresectable advanced/recurrent Non-Small Cell Lung Cancer (NSCLC)

Novocure announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer...

CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient: High-Precision Base Editing Clinical Treatment for Sickle Cell Disease

CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the first sickle...

Theravance Biopharma completes enrollment in Phase 3 CYPRESS study of Ampreloxetine for neurogenic orthostatic hypotension

Theravance Biopharma, Inc. announced completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), a rare and...

Jazz Pharmaceuticals announces the U.S. FDA approval of Modeyso™ (dordaviprone) as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso™ (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma...

Roche's first respiratory test, powered by TAGS technology, has received FDA clearance for SARS-CoV-2, Influenza A, Influenza B, and RSV

Roche announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for the cobas® Respiratory 4-flex. This is the first FDA-cleared assay utilizing Roche's innovative TAGS (Temperature-Activated Generation of Signal) technology, designed...

Neurocrine Biosciences Presents New Post-Hoc Data from the KINECT®-HD Study, Demonstrating a Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

Neurocrine Biosciences, Inc. announced new patient-reported post-hoc data from the KINECT®-HD study highlighting significant reductions in both cognitive and motor-related burdens among adults treated for Huntington's disease chorea with...

Avanzanite forms a Pan-European partnership with Agios to introduce PYRUKYND® for rare blood disorders

Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced an exclusive agreement with Agios Pharmaceuticals Inc. A...

Emulate introduces the AVA™ Emulation System, a groundbreaking high-throughput organ-chip platform designed to accelerate drug development

Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single...

Results 21 - 40 of 55